Medibact GuidesShop at Medibact

Stacking Module

Tesamorelin Stacking Module

Tesamorelin is the only GHRH analog here with a current FDA approval (Egrifta, for HIV-associated visceral fat), and that changes how its stacking should be read: there is a real label, real trial data and real monitoring guidance for the single compound, none of which extends to any combination.

Tesamorelin Guide at MedibactTesamorelin calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking Tesamorelin

  • Tesamorelin is a stabilized GHRH analog. Its complementary partner is a ghrelin-receptor secretagogue, not another GHRH analog.
  • It is an approved medicine for a specific indication. Its label includes glucose-tolerance monitoring guidance, which is a documented consideration no research-market GHRH analog carries.
  • Reported research use outside that indication is unapproved use, and the label's evidence does not transfer to it.
  • No controlled trial has studied Tesamorelin combined with anything.

Combinations in detail

Tesamorelin + Ipamorelin

GHRH analog + selective secretagogue
Why it is proposed
The standard two-pathway pairing using the approved GHRH analog. The rationale is identical to the CJC-1295 version; the difference is that this component has characterised pharmacology and a label.
What is reported in practice
Reported as a subcutaneous pairing; Tesamorelin's approved dosing is once daily.
Cautions specific to this combination
The label's glucose-monitoring guidance applies to the compound regardless of what it is combined with — and a secretagogue raising GH further is not neutral with respect to glucose handling. This is a genuine reason to involve a clinician.

Tesamorelin + GHRP-2

GHRH analog + older secretagogue
Why it is proposed
Same construction with a more potent secretagogue.
What is reported in practice
Reported as an alternate GHRH pairing in secretagogue discussion.
Cautions specific to this combination
Compounds the glucose consideration above, and adds GHRP-2's reported cortisol and prolactin effects.

What to avoid, and why

  • Pairing two GHRH analogs (Sermorelin, CJC-1295, Mod GRF 1-29, Tesamorelin) is described as redundant rather than additive — they act at the same receptor. Mod GRF 1-29 is CJC-1295 without the DAC modification, so combining those two is close to running one compound against itself.
  • Combining Tesamorelin with Sermorelin, CJC-1295 or Mod GRF 1-29 — all GHRH analogs.
  • Reading Egrifta trial data as support for a stack. That evidence covers one compound in one indication in a monitored population.

Related reading

Tesamorelin + Ipamorelin — Tesamorelin + IpamorelinThe Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.